synthesize

{
  "ranked_hypotheses": [
    {
      "title": "GFAP-positive reactive astrocyte states as mediators of regional metabolic vulnerability in AD requires proximal validation",
      "description": "The debate supports carrying forward GFAP-positive reactive astrocyte states as mediators of regional metabolic vulnerability in AD only if a proximal endpoint changes before the late outcome. The decisive validation path is: resolve GFAP-positive astrocyte subtypes by spatial transcriptomics and perturb metabolic support pathways in neuron-astrocyte systems.",
      "target_gene": "GFAP",
      "dimension_scores": {
        "evidence_strength": 0.57,
        "novelty": 0.64,
        "feasibility": 0.69,
        "therapeutic_potential": 0.58,
        "mechanistic_plausibility": 0.67,
        "druggability": 0.5,
        "safety_profile": 0.55,
        "competitive_landscape": 0.55,
        "data_availability": 0.63,
        "reproducibility": 0.66
      },
      "composite_score": 0.604,
      "evidence_for": [
        {
          "claim": "Preregistered claim: GFAP-positive reactive astrocytes mediate regional vulnerability through dysfunction of metabolic support, driving AD progression in affected regions",
          "source": "AD-MASTER-PLAN-GFAP-20260428030756"
        }
      ],
      "evidence_against": [
        {
          "claim": "GFAP is a state marker more than a specific intervention point, and reactive astrocytes can be protective or harmful",
          "source": "AD-MASTER-PLAN-GFAP-20260428030756"
        }
      ]
    },
    {
      "title": "Stratified falsifiers should govern AD Master Plan preregistration: GFAP",
      "description": "Claims from this analysis should be evaluated across GFAP, AD, tau, amyloid; pooled effects are insufficient when causal direction, cell state, genotype, benchmark leakage, or reproducibility risks can dominate the result.",
      "target_gene": "AD",
      "dimension_scores": {
        "evidence_strength": 0.54,
        "novelty": 0.59,
        "feasibility": 0.74,
        "therapeutic_potential": 0.5,
        "mechanistic_plausibility": 0.61,
        "druggability": 0.43,
        "safety_profile": 0.59,
        "competitive_landscape": 0.53,
        "data_availability": 0.68,
        "reproducibility": 0.7
      },
      "composite_score": 0.591,
      "evidence_for": [
        {
          "claim": "The analysis question names specific entities or evaluation structure.",
          "source": "AD-MASTER-PLAN-GFAP-20260428030756"
        }
      ],
      "evidence_against": [
        {
          "claim": "The current record can still be confounded by stage, leakage, or artifact effects.",
          "source": "AD-MASTER-PLAN-GFAP-20260428030756"
        }
      ]
    },
    {
      "title": "GFAP should remain under review until replicated",
      "description": "The consensus is to preserve this as a debated candidate, not a canonical world-model claim. Replication or rerun evidence should precede promotion into Atlas or market funding.",
      "target_gene": "tau",
      "dimension_scores": {
        "evidence_strength": 0.52,
        "novelty": 0.55,
        "feasibility": 0.71,
        "therapeutic_potential": 0.52,
        "mechanistic_plausibility": 0.58,
        "druggability": 0.45,
        "safety_profile": 0.58,
        "competitive_landscape": 0.52,
        "data_availability": 0.65,
        "reproducibility": 0.69
      },
      "composite_score": 0.577,
      "evidence_for": [
        {
          "claim": "Concrete next test: resolve GFAP-positive astrocyte subtypes by spatial transcriptomics and perturb metabolic support pathways in neuron-astrocyte systems",
          "source": "AD-MASTER-PLAN-GFAP-20260428030756"
        }
      ],
      "evidence_against": [
        {
          "claim": "Promotion before replication would weaken quality control.",
          "source": "AD-MASTER-PLAN-GFAP-20260428030756"
        }
      ]
    }
  ],
  "knowledge_edges": [
    {
      "source_id": "AD-MASTER-PLAN-GFAP-20260428030756",
      "source_type": "analysis",
      "target_id": "GFAP",
      "target_type": "entity",
      "relation": "debate_context_supports_review_of"
    },
    {
      "source_id": "AD-MASTER-PLAN-GFAP-20260428030756",
      "source_type": "analysis",
      "target_id": "AD",
      "target_type": "entity",
      "relation": "debate_context_supports_review_of"
    },
    {
      "source_id": "AD-MASTER-PLAN-GFAP-20260428030756",
      "source_type": "analysis",
      "target_id": "tau",
      "target_type": "entity",
      "relation": "debate_context_supports_review_of"
    },
    {
      "source_id": "AD-MASTER-PLAN-GFAP-20260428030756",
      "source_type": "analysis",
      "target_id": "amyloid",
      "target_type": "entity",
      "relation": "debate_context_supports_review_of"
    }
  ],
  "synthesis_summary": "Consensus: AD Master Plan preregistration: GFAP is substantive enough for debate because it names GFAP-positive reactive astrocyte states as mediators of regional metabolic vulnerability in AD and can be tied to a concrete validation path: resolve GFAP-positive astrocyte subtypes by spatial transcriptomics and perturb metabolic support pathways in neuron-astrocyte systems. Dissent: GFAP is a state marker more than a specific intervention point, and reactive astrocytes can be protective or harmful. The claim should remain under review until the falsifier or replication path is executed."
}